MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, April 7, 2013

MS Patients on Oral Therapies Are More Optimistic About Their Disease, According to Kantar Health Survey

Oral disease-modifying drugs are recent additions to the multiple sclerosis market.

New York, NY (PRWEB) April 03, 2013
Multiple sclerosis patients who are taking oral disease-modifying drugs (DMD) are more optimistic about their future expectations for their disease than patients who are taking non-oral DMDs, according to new research from Kantar Health, a leading global healthcare advisory firm.
More than 950 MS patients were asked to predict whether they expected their disease to improve, worsen or be the same in a year. Among patients taking oral DMDs, 34 percent expect their disease to be better and 49 percent expect their disease to worsen, compared with 16 percent of patients taking non-oral DMDs expecting their disease to improve and 62 percent expecting it to worsen.
Additionally, patients who take oral DMDs are more satisfied with their lives since starting their current treatment. Thirty-six percent of MS patients on oral DMDs are more satisfied with their lives since starting their current treatment, compared with 27 percent of patients taking non-oral DMD treatments.
About three in four of the DMD patients who plan to ask their physician to switch them to a specific brand say they will request an oral DMD. Still, many physicians seem hesitant to prescribe an oral DMD.
“Oral treatments for MS have been on the market for about two years, and we’re starting to see patients who have had a relapse in the past two years switching to the oral DMDs,” said Rose Lorenzo, director of research at Kantar Health. “While patients who have switched to oral DMDs are significantly more satisfied with their treatment, doctors are still wary about the lack of safety data and potential side effects. Both patients and physicians may be more open to oral treatments as additional data becomes available.”
About Kantar Health Syndicated Studies


USE OUR SHARE LINKS at the top of this page  - to provide this article to others

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left

REMAIN up to date with MS News and Education
Visit:  to register


No comments: